ATOS
Atossa Therapeutics, Inc. NASDAQ Listed Nov 8, 2012$5.74
Mkt Cap $49.4M
52w Low $3.76
12.7% of range
52w High $19.35
50d MA $5.19
200d MA $9.70
P/E (TTM)
-1.3x
EV/EBITDA
-0.9x
P/B
1.2x
Debt/Equity
0.0x
ROE
-88.3%
P/FCF
-2.6x
RSI (14)
—
ATR (14)
—
Beta
1.34
50d MA
$5.19
200d MA
$9.70
Avg Volume
116.1K
Atossa Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company that develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is based in Seattle, Washington.
CIK (SEC)
Phone
206 588 0256
107 Spring Street · Seattle, WA 98104 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 25, 2026 | AMC | -1.14 | -1.19 | -4.6% | 5.42 | -4.2% | -13.1% | +0.2% | -0.2% | +11.7% | -2.9% | — |
| Nov 12, 2025 | AMC | -1.05 | -1.05 | +0.0% | 12.20 | -2.0% | -1.3% | -0.3% | -1.8% | +0.6% | -3.4% | — |
| Aug 12, 2025 | AMC | -0.06 | -0.07 | -16.7% | 11.59 | -0.3% | +1.7% | -0.8% | -0.4% | +1.7% | -5.1% | — |
| May 13, 2025 | AMC | -0.06 | -0.05 | +16.7% | 13.35 | +4.5% | +15.7% | -4.3% | -1.6% | +1.4% | -4.2% | — |
| Mar 25, 2025 | AMC | -0.06 | -0.05 | +16.7% | 10.86 | +0.2% | -3.9% | +0.4% | -0.4% | -3.4% | -3.2% | — |
| Nov 12, 2024 | AMC | -0.06 | -0.05 | +16.7% | 22.50 | +0.0% | -8.7% | +0.0% | -6.6% | +0.0% | +0.0% | — |
| Aug 12, 2024 | AMC | -0.05 | -0.05 | +0.0% | 18.60 | +3.2% | +4.8% | -4.6% | +3.2% | +0.0% | +3.1% | — |
| May 13, 2024 | AMC | -0.07 | -0.05 | +28.6% | 21.90 | -2.1% | +5.5% | +4.5% | +0.0% | -2.5% | +1.9% | — |
| Apr 1, 2024 | AMC | -0.05 | -0.06 | -20.0% | 30.00 | +0.0% | -8.0% | +10.3% | +3.4% | -11.0% | -6.4% | — |
| Nov 13, 2023 | AMC | -0.07 | -0.05 | +28.6% | 9.47 | +1.4% | +1.6% | +2.0% | +4.0% | +0.0% | +8.8% | — |
| Aug 14, 2023 | AMC | -0.06 | -0.06 | +0.0% | 14.40 | -1.0% | -8.3% | +1.1% | -1.1% | +1.1% | +3.4% | — |
| May 15, 2023 | AMC | -0.06 | -0.05 | +16.7% | 10.65 | -1.4% | +0.0% | +0.0% | +0.0% | +2.8% | +0.0% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 10 | Ascendiant Capital | Maintains | Buy → Buy | — | $4.98 | $4.99 | +0.2% | -0.8% | +7.5% | +0.8% | +7.3% | +0.5% |
| Mar 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.42 | $5.19 | -4.2% | -13.1% | +0.2% | -0.2% | +11.7% | -2.9% |
| Dec 8 | Ascendiant Capital | Maintains | Buy → Buy | — | $11.99 | $12.30 | +2.6% | -2.3% | +3.5% | +5.1% | +6.4% | -8.8% |
| Sep 22 | Ascendiant Capital | Maintains | Buy → Buy | — | $12.73 | $12.64 | -0.7% | -2.1% | -1.0% | +0.3% | -1.1% | +5.1% |
| Jun 6 | Ascendiant Capital | Maintains | Buy → Buy | — | $12.90 | $13.05 | +1.2% | +4.7% | +1.6% | -3.1% | -0.8% | -1.7% |
| Apr 21 | Ascendiant Capital | Maintains | Buy → Buy | — | $9.35 | $9.35 | +0.0% | +2.1% | +4.2% | +11.3% | -0.7% | +3.2% |
| Mar 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.86 | $10.88 | +0.2% | -3.9% | +0.4% | -0.4% | -3.4% | -3.2% |
| Mar 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.11 | $11.10 | -0.1% | -3.2% | -4.4% | +5.1% | +1.4% | -0.7% |
| Jan 30 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $12.79 | $11.19 | -12.5% | +1.5% | -2.7% | +0.6% | -0.1% | +0.4% |
| Dec 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $17.25 | $17.25 | +0.0% | -2.6% | -4.5% | -2.8% | -4.8% | -1.0% |
| Dec 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $18.30 | $18.60 | +1.6% | -5.7% | -2.6% | -4.5% | -2.8% | -4.8% |
| Dec 9 | Ascendiant Capital | Maintains | Buy → Buy | — | $18.30 | $18.60 | +1.6% | +2.5% | +0.8% | -3.2% | -5.7% | -2.6% |
| Nov 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $22.50 | $22.50 | +0.0% | -8.7% | +0.0% | -6.6% | +0.0% | +0.0% |
| Nov 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $21.15 | $21.30 | +0.7% | -0.7% | +5.7% | +1.4% | +0.0% | +8.0% |
| Oct 31 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $21.15 | $21.15 | +0.0% | -2.1% | +2.9% | -0.7% | -0.7% | +5.7% |
| Sep 11 | Ascendiant Capital | Maintains | Buy → Buy | — | $21.90 | $21.60 | -1.4% | +4.1% | -1.3% | +1.3% | -0.7% | -4.0% |
| Aug 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $17.55 | $18.30 | +4.3% | +6.0% | +4.8% | -4.6% | +3.2% | +0.0% |
| Jun 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $17.10 | $17.70 | +3.5% | +4.4% | +0.8% | -3.3% | +0.9% | -6.8% |
| Jun 6 | Ascendiant Capital | Maintains | Buy → Buy | — | $19.65 | $20.10 | +2.3% | -3.1% | -1.6% | -4.0% | +3.3% | +3.2% |
| May 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $22.35 | $21.75 | -2.7% | -2.0% | +5.5% | +4.5% | +0.0% | -2.5% |
| Apr 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $25.65 | $25.05 | -2.3% | -9.9% | -12.3% | +5.2% | -3.5% | +3.6% |
| Apr 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $30.00 | $30.00 | +0.0% | -8.0% | +10.3% | +3.4% | -11.0% | -6.4% |
| Sep 17 | Ascendiant Capital | Maintains | Buy → Buy | — | $33.75 | $35.85 | +6.2% | +3.1% | +5.2% | -0.8% | -2.9% | +2.1% |
| Dec 18 | Maxim Group | Upgrade | Hold → Buy | — | $21.30 | $22.35 | +4.9% | +14.1% | +1.2% | -6.1% | +5.8% | -0.6% |
| Jan 26 | Maxim Group | Maintains | Buy → Buy | — | $59.40 | $64.80 | +9.1% | +27.3% | +40.5% | -8.5% | +48.1% | -12.5% |
| Oct 7 | Sidoti & Co. | Downgrade | Buy → Neutral | — | $14364.00 | $6912.00 | -51.9% | -46.4% | -14.0% | -13.5% | -3.8% | -6.9% |
| Apr 15 | Sidoti & Co. | Maintains | Buy → Buy | — | $23220.00 | $23301.00 | +0.3% | +2.8% | +1.9% | +6.4% | -5.0% | -10.1% |
| Mar 20 | Dawson James | Maintains | Market Outperform → Buy | — | $33399.00 | $33372.00 | -0.1% | -14.5% | +3.4% | +1.0% | +2.7% | -0.4% |
No insider trades available.
8-K · 2.02
!! High
Atossa Therapeutics, Inc. -- 8-K 2.02: Earnings Results
Atossa Therapeutics reported earnings results in an 8-K filing, with detailed financial performance and operational updates available in the attached press release for investor review.
May 8
8-K
Atossa Therapeutics, Inc. -- 8-K Filing
I cannot provide a meaningful analyst statement based on this summary, as it contains only technical metadata about SEC filing structure rather than substantive business information about Atossa Therapeutics.
May 8
8-K
Unknown — 8-K Filing
Atheneum Therapeutics resolved IP disputes over Endoxifen across oncology and rare diseases, clarifying development rights and reducing litigation risk for smoother commercialization of this multi-indication asset.
Apr 16
8-K
Unknown — 8-K Filing
Atossa's CFO transition and year-end 2025 results suggest potential leadership restructuring during a critical clinical-stage period, which could signal either strategic refocusing or financial/operational challenges investors should monitor closely.
Mar 25
8-K
Atossa Therapeutics, Inc. -- 8-K Filing
Atossa Therapeutics established an at-the-market offering agreement with a sales agent to raise capital for clinical development and general corporate purposes.
Feb 20
8-K
Atossa Therapeutics, Inc. -- 8-K Filing
This 8-K filing from Atossa Therapeutics discloses material events using structured domain taxonomy, but provides no specific business updates affecting investor valuation or stock performance.
Feb 17
8-K · 7.01
! Medium
Atossa Therapeutics, Inc. -- 8-K 7.01: Regulation FD Disclosure
Atossa Therapeutics disclosed shareholder communications via regulatory filing, providing investors updated information about company developments and strategic direction through management correspondence.
Feb 11
Data updated apr 24, 2026 7:39pm
· Source: massive.com